Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $12.50 billion. The enterprise value is $17.40 billion.
| Market Cap | 12.50B |
| Enterprise Value | 17.40B |
Important Dates
The next confirmed earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | May 16, 2024 |
Share Statistics
Royalty Pharma has 446.69 million shares outstanding. The number of shares has increased by 37.66% in one year.
| Shares Outstanding | 446.69M |
| Shares Change (YoY) | +37.66% |
| Shares Change (QoQ) | -0.61% |
| Owned by Insiders (%) | 3.83% |
| Owned by Institutions (%) | 72.18% |
| Float | 383.82M |
Valuation Ratios
The trailing PE ratio is 11.06 and the forward PE ratio is 7.03. Royalty Pharma's PEG ratio is 1.18.
| PE Ratio | 11.06 |
| Forward PE | 7.03 |
| PS Ratio | 5.31 |
| Forward PS | 4.68 |
| PB Ratio | 1.24 |
| P/FCF Ratio | 4.20 |
| PEG Ratio | 1.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.16, with an EV/FCF ratio of 5.85.
| EV / Earnings | 15.33 |
| EV / Sales | 7.39 |
| EV / EBITDA | 13.16 |
| EV / EBIT | 13.16 |
| EV / FCF | 5.85 |
Financial Position
The company has a current ratio of 7.90, with a Debt / Equity ratio of 0.61.
| Current Ratio | 7.90 |
| Quick Ratio | 7.87 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 4.64 |
| Debt / FCF | 2.06 |
| Interest Coverage | 7.06 |
Financial Efficiency
Return on equity (ROE) is 11.50% and return on invested capital (ROIC) is 9.20%.
| Return on Equity (ROE) | 11.50% |
| Return on Assets (ROA) | 6.80% |
| Return on Capital (ROIC) | 9.20% |
| Revenue Per Employee | $26.46M |
| Profits Per Employee | $12.75M |
| Employee Count | 89 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.91% in the last 52 weeks. The beta is 0.45, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.45 |
| 52-Week Price Change | -21.91% |
| 50-Day Moving Average | 29.66 |
| 200-Day Moving Average | 28.82 |
| Relative Strength Index (RSI) | 38.70 |
| Average Volume (30 Days) | 2,745,059 |
Short Selling Information
The latest short interest is 12.39 million, so 2.77% of the outstanding shares have been sold short.
| Short Interest | 12.39M |
| Short Previous Month | 12.65M |
| Short % of Shares Out | 2.77% |
| Short % of Float | 3.23% |
| Short Ratio (days to cover) | 5.11 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.35 billion and earned $1.13 billion in profits. Earnings per share was $2.53.
| Revenue | 2.35B |
| Gross Profit | 2.35B |
| Operating Income | 1.49B |
| Pretax Income | 1.13B |
| Net Income | 1.13B |
| EBITDA | 1.32B |
| EBIT | 1.32B |
| Earnings Per Share (EPS) | $2.53 |
Balance Sheet
The company has $1.23 billion in cash and $6.14 billion in debt, giving a net cash position of -$4.90 billion or -$10.97 per share.
| Cash & Cash Equivalents | 1.23B |
| Total Debt | 6.14B |
| Net Cash | -4.90B |
| Net Cash Per Share | -$10.97 |
| Equity / Book Value | 10.08B |
| Book Value Per Share | 22.58 |
| Working Capital | 1.11B |
Cash Flow
In the last 12 months, operating cash flow was $2.99 billion and capital expenditures -$12.40 million, giving a free cash flow of $2.98 billion.
| Operating Cash Flow | 2.99B |
| Capital Expenditures | -12.40M |
| Free Cash Flow | 2.98B |
| FCF Per Share | $6.65 |
Margins
Gross margin is 100.00%, with operating and profit margins of 63.37% and 48.20%.
| Gross Margin | 100.00% |
| Operating Margin | 63.37% |
| Pretax Margin | 48.20% |
| Profit Margin | 48.20% |
| EBITDA Margin | 56.15% |
| EBIT Margin | 56.15% |
| FCF Margin | 126.37% |
Dividends & Yields
This stock pays an annual dividend of $0.84, which amounts to a dividend yield of 3.00%.
| Dividend Per Share | $0.84 |
| Dividend Yield | 3.00% |
| Dividend Growth (YoY) | 5.13% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 33.20% |
| Buyback Yield | -37.66% |
| Shareholder Yield | -34.66% |
| Earnings Yield | 9.08% |
| FCF Yield | 23.81% |
Analyst Forecast
The average price target for Royalty Pharma is $46.75, which is 67.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.75 |
| Price Target Difference | 67.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 14.07% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.9 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 6 |